Literature DB >> 29318784

Divalproex sodium modulates nuclear localization of ataxin-3 and prevents cellular toxicity caused by expanded ataxin-3.

Zi-Jian Wang1,2,3,4, Aoife Hanet2,3,5, Daniel Weishäupl2,3,4, Inês M Martins2,3, Anna S Sowa2,3,4, Olaf Riess2,3, Thorsten Schmidt2,3.   

Abstract

BACKGROUND & AIMS: Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease (MJD), is an autosomal dominantly inherited neurodegenerative disorder and the most common form of SCA worldwide. It is caused by the expansion of a polyglutamine (polyQ) tract in the ataxin-3 protein. Nuclear localization of the affected protein is a key event in the pathology of SCA3 via affecting nuclear organization, transcriptional dysfunction, and seeding aggregations, finally causing neurodegeneration and cell death. So far, there is no effective therapy to prevent or slow the progression of SCA3.
METHODS: In this study, we explored the effect of divalproex sodium as an HDACi in SCA3 cell models and explored how divalproex sodium interferes with pathogenetic processes causing SCA3.
RESULTS: We found that divalproex sodium rescues the hypoacetylation levels of histone H3 and attenuates cellular cytotoxicity induced by expanded ataxin-3 partly via preventing nuclear transport of ataxin-3 (particularly heat shock-dependent).
CONCLUSION: Our study provides novel insights into the mechanisms of action of divalproex sodium as a possible treatment for SCA3, beyond the known regulation of transcription.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  HDAC inhibitors; SCA3 treatment; divalproex sodium; nuclear localization; transcriptional dysfunction

Mesh:

Substances:

Year:  2018        PMID: 29318784      PMCID: PMC6489778          DOI: 10.1111/cns.12795

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  67 in total

1.  Nucleosome linking number change controlled by acetylation of histones H3 and H4.

Authors:  V G Norton; K W Marvin; P Yau; E M Bradbury
Journal:  J Biol Chem       Date:  1990-11-15       Impact factor: 5.157

Review 2.  Regulation of nuclear transport: central role in development and transformation?

Authors:  Ivan K H Poon; David A Jans
Journal:  Traffic       Date:  2005-03       Impact factor: 6.215

3.  Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3.

Authors:  H L Paulson; M K Perez; Y Trottier; J Q Trojanowski; S H Subramony; S S Das; P Vig; J L Mandel; K H Fischbeck; R N Pittman
Journal:  Neuron       Date:  1997-08       Impact factor: 17.173

4.  Identification and functional dissection of localization signals within ataxin-3.

Authors:  Paul Michel Aloyse Antony; Simone Mäntele; Phillip Mollenkopf; Jana Boy; Ralph H Kehlenbach; Olaf Riess; Thorsten Schmidt
Journal:  Neurobiol Dis       Date:  2009-08-04       Impact factor: 5.996

5.  Study of subcellular localization and proteolysis of ataxin-3.

Authors:  Chiara Pozzi; Marco Valtorta; Gabriella Tedeschi; Elena Galbusera; Valentina Pastori; Alessandra Bigi; Simona Nonnis; Eleonora Grassi; Paola Fusi
Journal:  Neurobiol Dis       Date:  2008-02-15       Impact factor: 5.996

6.  Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice.

Authors:  I A Klement; P J Skinner; M D Kaytor; H Yi; S M Hersch; H B Clark; H Y Zoghbi; H T Orr
Journal:  Cell       Date:  1998-10-02       Impact factor: 41.582

7.  Proteotoxic stress increases nuclear localization of ataxin-3.

Authors:  Christopher P Reina; Xiaoyan Zhong; Randall N Pittman
Journal:  Hum Mol Genet       Date:  2009-10-19       Impact factor: 6.150

8.  Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence.

Authors:  Ulrike Bichelmeier; Thorsten Schmidt; Jeannette Hübener; Jana Boy; Lukas Rüttiger; Karina Häbig; Sven Poths; Michael Bonin; Marlies Knipper; Werner J Schmidt; Johannes Wilbertz; Hartwig Wolburg; Franco Laccone; Olaf Riess
Journal:  J Neurosci       Date:  2007-07-11       Impact factor: 6.167

9.  SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease.

Authors:  Michal Mielcarek; Caroline L Benn; Sophie A Franklin; Donna L Smith; Ben Woodman; Paul A Marks; Gillian P Bates
Journal:  PLoS One       Date:  2011-11-28       Impact factor: 3.240

10.  Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease.

Authors:  Emma Hockly; Victoria M Richon; Benjamin Woodman; Donna L Smith; Xianbo Zhou; Eddie Rosa; Kirupa Sathasivam; Shabnam Ghazi-Noori; Amarbirpal Mahal; Philip A S Lowden; Joan S Steffan; J Lawrence Marsh; Leslie M Thompson; Cathryn M Lewis; Paul A Marks; Gillian P Bates
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-07       Impact factor: 11.205

View more
  3 in total

1.  Divalproex sodium modulates nuclear localization of ataxin-3 and prevents cellular toxicity caused by expanded ataxin-3.

Authors:  Zi-Jian Wang; Aoife Hanet; Daniel Weishäupl; Inês M Martins; Anna S Sowa; Olaf Riess; Thorsten Schmidt
Journal:  CNS Neurosci Ther       Date:  2018-01-09       Impact factor: 5.243

2.  Sodium valproate increases activity of the sirtuin pathway resulting in beneficial effects for spinocerebellar ataxia-3 in vivo.

Authors:  Maxinne Watchon; Luan Luu; Katherine J Robinson; Kristy C Yuan; Alana De Luca; Hannah J Suddull; Madelaine C Tym; Gilles J Guillemin; Nicholas J Cole; Garth A Nicholson; Roger S Chung; Albert Lee; Angela S Laird
Journal:  Mol Brain       Date:  2021-08-20       Impact factor: 4.041

Review 3.  Transcriptional Dysregulation and Post-translational Modifications in Polyglutamine Diseases: From Pathogenesis to Potential Therapeutic Strategies.

Authors:  Chunchen Xiang; Shun Zhang; Xiaoyu Dong; Shuang Ma; Shuyan Cong
Journal:  Front Mol Neurosci       Date:  2018-05-15       Impact factor: 5.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.